Published News

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics. To order this 530+ page report, which features 160+ figures and 190+ tables, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:  Phase of development  Approved  Pre-registration & Phase III  Phase II & Phase II/III  Type of molecule  Cell and gene therapies  Monoclonal antibodies  Proteins  Peptides (recombinant)  Vaccines  Others  Target therapeutic area  Autoimmune disorders  Blood disorders  Bone disorders  Genetic disorders  Metabolic disorders  Neurological disorders  Oncological disorders  Respiratory disorders  Others  Type of drug delivery system  Large volume wearable injectors  Autoinjectors  Prefilled syringes  Needle-free injectors  Drug reconstitution systems  Revenues from licensing deals  Upfront payments  Milestone payments  Key geographical regions  North America  Europe  Asia Pacific  Rest of the World The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:  Adocia  Ajinomoto Bio-Pharma Services  Arecor  Alteogen  Ascendis Pharma  Avadel Pharmaceuticals  Camurus  Creative BioMart  Creative Biolabs  DURECT  Eagle Pharmaceuticals  Halozyme Therapeutics  MedinCell  Xeris Pharmaceuticals  Serina Therapeutics Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Subcutaneous Biologics: Current Market Landscape 5. Case Study: Leading Subcutaneous Biologics 6. Subcutaneous Formulation Technologies: Current Market Landscape 7. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis 8. Subcutaneous Formulation Technology Developers: Company Profiles 9. Partnerships and Collaborations 10. Subcutaneous Drug Delivery Systems: Current Market Landscape 11. Swot Analysis 12. Market Forecast and Opportunity Analysis 13. Concluding Remarks 14. Executive Insights 15. Appendix 1: Tabulated Data 16. Appendix 2: List Of Companies And Organization To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment To order this 485+ page report, which features 195+ figures and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-/267.html The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:  Type of molecule  Small Molecule  Biologic  Target disease indication  Breast Cancer  Colorectal Cancer  Fallopian Tube Cancer  Gastric Cancer  Head and Neck Cancer  Lung Cancer  Ovarian Cancer  Peritoneal Cancer  Others  Type of synlet target  APE1 / Ref-1  Chk1  GLS1  PARP  Pol θ  PP2A  Wee1  Route of administration  Oral  Intravenous  Key geographical regions  North America  Europe  Asia Pacific  Rest of the World The https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html, report features the following companies, which we identified to be key players in this domain:  AbbVie  AstraZeneca  AtlasMedx  BeiGene  Chordia Therapeutics  Clovis Oncology  GlaxoSmithKline  IDEAYA Biosciences  Mission Therapeutics  Pfizer  Repare Therapeutics  Sierra Oncology  SyntheX Labs Table of Contents 1. Preface 2. Executive Summary 3. Introduction to DNA Damage and Repair Systems 4. Introduction to Synthetic Lethality 5. Market Overview 6. Company Profiles 7. Emerging Trends on Social Media 8. Publication Analysis 9. Abstract Analysis 10. Academic Grants Analysis 11. Funding and Investment Analysis 12. Target Benchmark Analysis 13. Role of Companion Diagnostics in Synthetic Lethality 14. Market Forecast 15. Concluding Remarks 16. Executive Insights 17. Appendix 1: Tabulated Data 18. Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

To order this 330+ page report, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Key Inclusions  A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.  Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.  Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.  A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.  An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).  A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.  An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.  An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Type of payment of licensing agreements  Upfront payments  Milestone payments  Type of protein degrader  Degronimids  PROTACs  SARDs / SERDs  Specific BET and DUB inhibitors  Other protein degraders  Therapeutic area  Neurodegenerative disorders  Oncological disorders  Other therapeutic areas  Route of administration  Oral  Intravenous  Other routes  Key geographical region  North America  Europe  Asia-Pacific To request a sample pages, please visit https://www.rootsanalysis.com/reports/289/request-sample.html Key Questions Answered  What are the prevalent R&D trends related to targeted protein degradation?  Which clinical conditions can be treated using targeted protein degradation-based therapeutics?  What are the most popular proteins being targeted by bifunctional degrader molecules?  What are the key challenges faced by stakeholders engaged in this domain?  What are the key technology platforms that leverage the concept of targeted protein degradation?  Who are the leading industry and non-industry players in this market?  What are the contributions of big pharma players in this field?  What are the key geographies where research on targeted protein degradation is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? You may also be interested in the following titles: 1. DNA-Encoded Libraries: Platforms and Services Market 2. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 3. The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

Our mission is to automate up to 90% of your business by connecting apps like Slack, Zendesk and Asana (and thousands of others) to make it easier for you to do your work. We'll help you get productive at your job by automating repetitive tasks.

เว็บไซต์แทงบอล เป็นความแตกต่างอย่างเห็นได้ชัดในการพนันบอลในอดีตกับปัจจุบันซึ่งเมื่อก่อนกับการพนันบอลกับโต๊ะพนันบอลต่างๆซึ่งจะมีข้อกำหนดอยู่หลายประเภทด้วยกัน และยังเป็นผลเสียโดยตรงต่อนักเสี่ยงโชคบอลทุกคนโดยตรงอีกด้วยไม่ว่าจะเป็นความสิ้นเปลืองค่าครองชีพ

ufabet978 เป็นโอกาสที่ดีสำหรับนักเล่นการพนันทุกคนที่กำลังมองหาหนทางสำหรับการลงทุนให้กับตัวเองกับการทดลองสมัครเข้ามาเป็นสมาชิกกับเว็บพนันออนไลน์ยูฟ่าเบท 978 ซึ่งเป็นช่องทางสำหรับเพื่อการวางเดิมพันกับเกมการเดิมพันออนไลน์ทุกชนิดได้สม่ำเสมอตลอดเวลา

UFABET เป็นการตอบปัญหาในสิ่งที่มีความต้องการให้กับนักเสี่ยงโชคทุกคนได้เป็นอย่างดี สำหรับเว็บไซต์พนันออนไลน์ยูฟ่าเบท กับความมากมายของเกมการพนันออนไลน์ทุกชนิดไม่ว่าจะเป็นเกมส์การพนันชนิดกีฬาต่างๆเป็นต้นว่าการพนันบอลออนไลน์และก็กีฬาอื่นๆอีกเป็นจำนวนมากอีกด้วย

เว็บไซต์พนันบอล อย่างน้อย10บาท ลงทุนน้อยรายได้งามกับแทงบอลสเต็ปอย่างต่ำ 10บาท เว็บไซต์แทงบอล ขั้นต่ำ10บาท เป็นการตั้งเงื่อนไขการวางเดิมพันในอัตราอย่างต่ำเพียงแค่ 10 บาทขึ้นไปเท่านั้นรวมทั้งคงจะเหมาะมากสำหรับในการแทงบอลสเต็ป

แทงบอล โกงอย่างไร คนพาลชอบอยู่ทั่วๆไปในสังคม เว็บไซต์พนันที่ไม่ดีก็เช่นเดียวกันถือได้ว่าอันตรายอย่างยิ่งต่อการเข้าไปเล่นพนันบอล โดยไม่พินิจพิจารณาให้ถี่ถ้วนโดยเลือกเว็บพนันที่ปราศจากความมั่นคงทางการเงิน จึงควรมองเป็นอันดับแรก

เว็บพนันบอล 168 เว็บที่มีโปรโมชั่นดีๆรวมทั้งมีการให้บริการที่ดีมาก เว็บพนันบอล 168 เป็นเว็บที่แพงบอลที่เหมาะสมที่สุดและยังมีค่าคอมมิชชั่นที่สูงที่สุดอีกด้วย ถือว่าอยู่ระดับเดียวกับเว็บไซต์ยูฟ่าเบทเลย อีกทั้งยังเป็นเว็บที่มีความมั่นคงยั่งยืนทางด้านการเงินทำให้เรามั่นอกมั่นใจได้เลยว่าไม่ว่าเราจะแทงบอลออนไลน์ได้ในตอนไหนก็จะได้รับเงินโอนฝากบัญชีในช่วงเวลานั้นเลยโดยที่ไม่โดนหักค่าใช้สอยอะไรก็แล้วแต่และไม่มีการเบี้ยวเงินหรือหลอกลวงเงินเกิดขึ้นในเว็บนี้อย่างแน่นอน